Abstract

Background— The primary objective of this mechanistic open-label, stratified clinical trial was to determine the effect of 8 weeks’ sodium glucose cotransporter 2 inhibition with empagliflozin 25 mg QD on renal hyperfiltration in subjects with type 1 diabetes mellitus (T1D). Methods and Results— Inulin (glomerular filtration rate; GFR) and paraaminohippurate (effective renal plasma flow) clearances were measured in individuals stratified based on having hyperfiltration (T1D-H, GFR ≥ 135 mL/min/1.73m 2 , n=27) or normal GFR (T1D-N, GFR 90–134 mL/min/1.73m 2 , n=13) at baseline. Renal function and circulating levels of renin-angiotensin-aldosterone system mediators and NO were measured under clamped euglycemic (4–6 mmol/L) and hyperglycemic (9–11 mmol/L) conditions at baseline and end of treatment. During clamped euglycemia, hyperfiltration was attenuated by −33 mL/min/1.73m 2 with empagliflozin in T1D-H, (GFR 172±23–139±25 mL/min/1.73 m 2 , P <0.01). This effect was accompanied by declines in plasma NO and effective renal plasma flow and an increase in renal vascular resistance (all P <0.01). Similar significant effects on GFR and renal function parameters were observed during clamped hyperglycemia. In T1D-N, GFR, other renal function parameters, and plasma NO were not altered by empagliflozin. Empagliflozin reduced hemoglobin A1c significantly in both groups, despite lower insulin doses in each group ( P ≤0.04). Conclusions— In conclusion, short-term treatment with the sodium glucose cotransporter 2 inhibitor empagliflozin attenuated renal hyperfiltration in subjects with T1D, likely by affecting tubular-glomerular feedback mechanisms. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT01392560.

Keywords

EmpagliflozinMedicineRenal functionGlomerular hyperfiltrationInternal medicineEffective renal plasma flowEndocrinologyRenal blood flowDiabetes mellitusTubuloglomerular feedbackPlasma renin activityAldosteroneFiltration fractionType 2 diabetesUrologyRenin–angiotensin systemBlood pressureDiabetic nephropathy

Affiliated Institutions

Related Publications

Publication Info

Year
2013
Type
article
Volume
129
Issue
5
Pages
587-597
Citations
1244
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1244
OpenAlex

Cite This

David Z.I. Cherney, Bruce A. Perkins, Nima Soleymanlou et al. (2013). Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus. Circulation , 129 (5) , 587-597. https://doi.org/10.1161/circulationaha.113.005081

Identifiers

DOI
10.1161/circulationaha.113.005081